Trial Profile
Phase II Study to Investigate the Properties of Topical Twice Daily Doses of 2.5% and 5% Cis-urocanic Acid in Comparison to Active Comparator 0.1% Protopic® for up to 28 Days in Patients With Moderate or Severe Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2014
Price :
$35
*
At a glance
- Drugs Urocanic acid (Primary) ; Tacrolimus
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors BioCis Pharma
- 19 Dec 2014 New trial record